The CFTR corrector molecules VX-809 and VX-661, each used in combination with VX-770 were approved for patients harboring two copies of Phe508del, the most common CF-causing variant, though the clinical efficacy has been modest (2.6–4% FEV1 increase)5,9. This evidence concerns the gene CFTR and cystic fibrosis.